PFE - CureVac - Pfizer/BioNTech patent fight extends to updated COVID shots

2023-07-13 11:54:05 ET

CureVac ( NASDAQ: CVAC ) announced Thursday it widened the legal scope of its patent litigation, with Pfizer ( PFE ) and BioNTech ( BNTX ) bringing additional claims of patent infringement in a German court to challenge the companies' updated COVID vaccines.

With the addition of three new patent intellectual property rights linked to variant-adapted vaccines, CureVac ( CVAC ) is asserting eight IP rights in its German lawsuit against the COVID-19 vaccine makers.

The litigation filed in June 2022 is set for its first public hearing on August 15, 2023, before the Regional Court Düsseldorf, the German vaccine developer said.

CureVac ( CVAC ) has also expanded its U.S. lawsuit against Pfizer ( PFE ) and BioNTech ( BNTX ) to add a tenth patent related to the mRNA manufacturing process.

With the addition of new IP rights to the lawsuits "CureVac not only extends the scope of the cases in both jurisdictions but demonstrates that we continue to be at the forefront of innovation in the mRNA field," CEO Alexander Zehnder remarked.

More on the patent battle

• CureVac accelerates COVID patent dispute with Pfizer/BioNTech as court grants motion
• CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine

For further details see: